Editorial: Small cell lung cancer: New drugs and strategies

Editorial: Small cell lung cancer: New drugs and strategies

Bibliographic Details
Main Authors:	Diego L. Cortinovis, Alessandro Morabito
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Medicine
Subjects:	SCLC immunotherapy lurbinectedin anti-DLL3 drugs Aurora kinase inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1140642/full

Similar Items

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
by: Kauffmann-Guerrero D, et al.
Published: (2020-03-01)

Lurbinectedin in small cell lung cancer
by: Anna Manzo, et al.
Published: (2022-08-01)

Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer
by: Huan Zhang, et al.
Published: (2023-03-01)

Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody–Drug Conjugates
by: Lorenzo Belluomini, et al.
Published: (2023-11-01)

Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma
by: Diego Cortinovis, et al.
Published: (2021-03-01)

Expression patterns and clinical implications of PDL1 and DLL3 biomarkers in small cell lung cancer retrospectively studied: Insights for therapeutic strategies and survival prediction
by: Kalliopi Domvri, et al.
Published: (2024-03-01)

Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity
by: Mohammad Hossein Ataee, et al.
Published: (2022-01-01)

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
by: Salvador Fudio, et al.
Published: (2023-06-01)

ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China
by: Chunfang Hu, et al.
Published: (2022-02-01)

PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer
by: Fu X, et al.
Published: (2020-10-01)

Small cell lung cancer: an overview of the targets
by: Bruna Nardy Valadares, et al.
Published: (2022-05-01)

Small-Cell Lung Cancer—An Update on Targeted and Immunotherapies
by: Nicholas McNamee, et al.
Published: (2023-05-01)

Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis
by: Benchao Chen, et al.
Published: (2020-08-01)

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
by: Rebekah Rittberg, et al.
Published: (2022-12-01)

Advances in new targets for immunotherapy of small cell lung cancer
by: Zitong Zheng, et al.
Published: (2024-01-01)

New therapies in small cell lung cancer: A narrative review
by: Sotirios Papavasileiou, et al.
Published: (2024-03-01)

Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trials
by: Vito Longo, et al.
Published: (2023-04-01)

Editorial: Updates on combination therapy for lung cancer volume II
by: Alberto Pavan, et al.
Published: (2024-04-01)

SCLC-J1, a novel small cell lung cancer cell line
by: Kazuo Ohara, et al.
Published: (2021-09-01)

Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies
by: Nicholas R. Liguori, et al.
Published: (2021-08-01)

Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients
by: Siggelkow Wulf, et al.
Published: (2012-11-01)

Expression of Aurora Kinase A and B in chondrosarcoma and its relationship with the prognosis
by: Liang Xiaohui, et al.
Published: (2012-07-01)

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study
by: Irene Moreno, et al.
Published: (2024-01-01)

Aurora B Inhibitors as Cancer Therapeutics
by: Antal H. Kovacs, et al.
Published: (2023-04-01)

Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
by: Arani Sathiyapalan, et al.
Published: (2022-11-01)

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)
by: Hidenobu Ishii, et al.
Published: (2023-01-01)

Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile
by: Jean Camille Mattei, et al.
Published: (2020-03-01)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
by: Giovanni Martinelli, et al.
Published: (2009-02-01)

When Just One Phosphate Is One Too Many: The Multifaceted Interplay between Myc and Kinases
by: Dalila Boi, et al.
Published: (2023-03-01)

Extensive Stage Small-Cell Lung Cancer with Cystic Brain Metastases: A Report of Two Cases
by: Cai F, et al.
Published: (2024-03-01)

Tracheal polypoid combined small cell lung cancer (C‐SCLC): A case report
by: Alberto Testori, et al.
Published: (2021-07-01)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
by: Shuang Zhang, et al.
Published: (2023-04-01)

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer
by: Christopher W Schultz, et al.
Published: (2023-08-01)

Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer
by: Alessio Stefani, et al.
Published: (2022-10-01)

Immunotherapy in Small Cell Lung Cancer
by: Antonio Rossi
Published: (2019-06-01)

Pathology and Classification of SCLC
by: Maria Gabriela Raso, et al.
Published: (2021-02-01)

An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression
by: Jaewook Ryu, et al.
Published: (2018-11-01)

In-Silico Identification of Novel Pharmacological Synergisms: The Trabectedin Case
by: Laura Mannarino, et al.
Published: (2024-02-01)

Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting
by: Jacob Sands, et al.
Published: (2023-12-01)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
by: Alberto Zambelli, et al.
Published: (2023-01-01)